Health Care Professional survey on understanding of key risk minimisation measures related to interstitial lung disease (ILD) / pneumonitis with Trastuzumab Deruxtecan treatment

First published 24/03/2022

Last updated 27/05/2024

EU PAS number:

EUPAS46367

Study

Finalised

Documents

Study protocol

Initial protocol

DSE_T-DXd_HCP Survey_Protocol_v1.0_20Dec2021_blackened

English (463.16 KB - PDF)View document

Study results

Study report

EUPAS46367_Report Abstract_May 2024.pdf

English (168.84 KB - PDF)View document

Other information

Secondary tabs